CYTOKINETICS INC — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Cytokinetics reported Q3 2026 net product revenue of $44.5 million from MYQORZO (aficamten) in the U.S. ($43.1M) and Europe ($1.4M). The company has nearly 1,100 prescribers and over 2,800 patients on the drug year-to-date. Cash and investments totaled $1.6 billion as of September 30, 2026 (down from $1.7B in Q2 2026). The company plans to submit a Supplemental NDA for non-obstructive HCM in Q4 2026 and a Type II Variation in the EU in early 2027, following positive ACACIA-HCM Phase 3 trial results. MYQORZO received regulatory approval in Canada and the UK; launch in the UK is planned for Q4 2026.
Why this rating
First commercial revenue ($44.5M quarterly = ~1.8% of $2.5B market cap) shows MYQORZO traction; regulatory expansion (Canada, UK approval) validates drug; cash ($1.6B) supports operations. Moderate significance: revenue is early-stage, company still burning ~$210M/quarter operating losses; but milestone progress in multi-indication strategy.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.